This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.

Inclusion Criteria:

• Best corrected visual acuity (ETDRS scale) of 60 letters or less in the study eye.
• An active choroidal neovascular membrane attributable to neovascular AMD in at least one eye.
• History of treatment (at any time) with at least 3 doses of anti-VEGF therapy in the study eye.

Exclusion Criteria:

• History of recurrent non-response to anti-VEGF therapy in the study eye.
• In the study eye, retinal disease other than AMD (benign conditions of the vitreous and peripheral retina are not exclusionary).
• Choroidal neovascularization due to a cause other than AMD.
• In the study eye, media opacity that, in the investigator's opinion, could interfere with conduct of the study.
• History of infectious uveitis or endophthalmitis in either eye.
• Any of the following treatments to the study eye within 28 days prior to dosing: ranibizumab, bevacizumab, pegaptanib or other VEGF inhibitor.
• Any of the following within 90 days prior to dosing: photodynamic therapy or laser photocoagulation in the study eye; intravitreal steroid in the study eye; or intraocular surgery (including cataract surgery) in the study eye